This article includes a list of general references, but it lacks sufficient corresponding inline citations .(October 2021) |
L-Homoarginine | |
Names | |
---|---|
IUPAC name (2S)-2-Amino-6-(diaminomethylideneamino)hexanoic acid | |
Other names
| |
Identifiers | |
3D model (JSmol) | |
ChemSpider | |
EC Number |
|
PubChem CID | |
UNII | |
| |
| |
Properties | |
C7H16N4O2 | |
Molar mass | 188.231 g·mol−1 |
Appearance | White crystalline powder |
Density | 1.39 g/cm−3 |
Boiling point | 414.1 °C (777.4 °F; 687.2 K) 760 mmHg |
soluble | |
Vapor pressure | 1.06x10–6 mmHg at 25°C |
Refractive index (nD) | 1.586 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). |
Homoarginine is an nonproteinogenic alpha-amino acid. It is structurally equivalent to a one-methylene group-higher homolog of arginine and to the guanidino derivative of lysine. L-Homoarginine is the naturally-occurring enantiomer. Physiologically, homoarginine increases nitric oxide (NO) supply and betters endothelial functions in the body, with a particular correlation and effect towards cardiovascular outcome and mortality. At physiological pH, homoarginine is cationic: the guanidino group is protonated.
Homoarginine is a growth inhibitor of Staphylococcus aureus , Escherichia Coli and Candida albicans , indicating it inhibits particular microbial growth and germination pathways. Homoarginine is assumed to be an antimetabolite of arginine. Many studies have shown that it acts as a competitive inhibitor in most cases, but there are also controversial studies showing that it is also an organ specific, non-competitive inhibitor as well. Studies have also shown that it is toxic when targeting Insecta and Rattus norvegicus. In its inhibition, is also often found in occurrences with the lungs, cervix, testis and is an inhibitor of bone and liver-specific alkaline phosphatase enzymes. This amino acid derivative is also found in occurrence with murine osteosarcoma cell proliferation.
Levels of homoarginine have been found to increase during pregnancy, but more studies are underway to confirm this thoroughly.
Homoarginine is formed as a derivative from lysine through reactions similar to those of the urea cycle. Just as in the urea cycle, in its synthesis, ornithine is replaced by lysine. Ornithine transcarbamylase is the main enzyme for homoarginine synthesis. The production of homoarginine is based around the activity of this enzyme. Although ornithine transcarbamylase has a higher affinity to ornithine, it ends up catalyzing the transaminidation reaction of lysine as well, which starts homoarginine production. The reason it also catalyzes this reaction with lysine is because of the low substrate selectivity in the reaction.
Another pathway for the production of Homoarginine includes glycine amidinotransferase (AGAT). This enzyme normally acts through the transfer of an amidino group from arginine to glycine, resulting in formation of guanidinoacetic acid, which is subsequently methylated by guanidinoacetate methyltransferase (GAMT) to form creatine. However, glycine amidinotransferase (AGAT) sometimes acts by using lysine instead of glycine in the reaction, therefore lysine becomes the acceptor of the amidino group, resulting in the production of homoarginine.
Homoarginine can increase the availability of nitric oxide, and this is the basis of many of its functions. It can serve as a substrate for NO synthase itself. It can also inhibit arginase, an enzyme that competes with NO synthase for arginine. The resulting increase in the intracellular concentration of arginine leads to increased production of NO from it by NO synthase.
Homoarginine is used clinical studies, often with rats, to explore its effects on cardiovascular health by acting as an inhibitor for organ-specific reactions as well as a stimulator in some cases.
A recent study was done on the topic of homoarginine related to heart failure and sudden cardiac death in haemodialysis patients. The study was done on 1255 diabetic haemodialysis patients throughout a median of 4 years of follow-up. Results showed a range of different events such as sudden cardiac death, myocardial infarction, stroke, and even death due to heart failure. The study calculations showed that the risk of sudden cardiac death had a three fold increase in the presence of per unit decrease of homoarginine. This explained the strong association of congestive heart failure and left ventricular hypertrophy with low homoarginine levels. Furthermore, this study presented evidence towards increased risk of stroke with low concentrations of homoarginine. Yet, some cases such as myocardial infarction did not show any significance towards low levels of homoarginine correlation.
α-Ketoglutaric acid is a keto acid.
Arginine is the amino acid with the formula (H2N)(HN)CN(H)(CH2)3CH(NH2)CO2H. The molecule features a guanidino group appended to a standard amino acid framework. At physiological pH, the carboxylic acid is deprotonated (−CO2−) and both the amino and guanidino groups are protonated, resulting in a cation. Only the l-arginine (symbol Arg or R) enantiomer is found naturally. Arg residues are common components of proteins. It is encoded by the codons CGU, CGC, CGA, CGG, AGA, and AGG. The guanidine group in arginine is the precursor for the biosynthesis of nitric oxide. Like all amino acids, it is a white, water-soluble solid.
Ornithine is a non-proteinogenic amino acid that plays a role in the urea cycle. Ornithine is abnormally accumulated in the body in ornithine transcarbamylase deficiency. The radical is ornithyl.
The organic compound citrulline is an α-amino acid. Its name is derived from citrullus, the Latin word for watermelon. Although named and described by gastroenterologists since the late 19th century, it was first isolated from watermelon in 1914 by Japanese researchers Yotaro Koga and Ryo Odake and further codified by Mitsunori Wada of Tokyo Imperial University in 1930. It has the formula H2NC(O)NH(CH2)3CH(NH2)CO2H. It is a key intermediate in the urea cycle, the pathway by which mammals excrete ammonia by converting it into urea. Citrulline is also produced as a byproduct of the enzymatic production of nitric oxide from the amino acid arginine, catalyzed by nitric oxide synthase.
Ornithine transcarbamylase (OTC) is an enzyme that catalyzes the reaction between carbamoyl phosphate (CP) and ornithine (Orn) to form citrulline (Cit) and phosphate (Pi). There are two classes of OTC: anabolic and catabolic. This article focuses on anabolic OTC. Anabolic OTC facilitates the sixth step in the biosynthesis of the amino acid arginine in prokaryotes. In contrast, mammalian OTC plays an essential role in the urea cycle, the purpose of which is to capture toxic ammonia and transform it into urea, a less toxic nitrogen source, for excretion.
Hyperammonemia is a metabolic disturbance characterised by an excess of ammonia in the blood. It is a dangerous condition that may lead to brain injury and death. It may be primary or secondary.
Arginase (EC 3.5.3.1, arginine amidinase, canavanase, L-arginase, arginine transamidinase) is a manganese-containing enzyme. The reaction catalyzed by this enzyme is:
Aminolevulinic acid synthase (ALA synthase, ALAS, or delta-aminolevulinic acid synthase) is an enzyme (EC 2.3.1.37) that catalyzes the synthesis of δ-aminolevulinic acid (ALA) the first common precursor in the biosynthesis of all tetrapyrroles such as hemes, cobalamins and chlorophylls. The reaction is as follows:
Pyridoxal phosphate (PLP, pyridoxal 5'-phosphate, P5P), the active form of vitamin B6, is a coenzyme in a variety of enzymatic reactions. The International Union of Biochemistry and Molecular Biology has catalogued more than 140 PLP-dependent activities, corresponding to ~4% of all classified activities. The versatility of PLP arises from its ability to covalently bind the substrate, and then to act as an electrophilic catalyst, thereby stabilizing different types of carbanionic reaction intermediates.
Nitric oxide synthases (NOSs) are a family of enzymes catalyzing the production of nitric oxide (NO) from L-arginine. NO is an important cellular signaling molecule. It helps modulate vascular tone, insulin secretion, airway tone, and peristalsis, and is involved in angiogenesis and neural development. It may function as a retrograde neurotransmitter. Nitric oxide is mediated in mammals by the calcium-calmodulin controlled isoenzymes eNOS and nNOS. The inducible isoform, iNOS, involved in immune response, binds calmodulin at physiologically relevant concentrations, and produces NO as an immune defense mechanism, as NO is a free radical with an unpaired electron. It is the proximate cause of septic shock and may function in autoimmune disease.
In molecular biology, biosynthesis is a multi-step, enzyme-catalyzed process where substrates are converted into more complex products in living organisms. In biosynthesis, simple compounds are modified, converted into other compounds, or joined to form macromolecules. This process often consists of metabolic pathways. Some of these biosynthetic pathways are located within a single cellular organelle, while others involve enzymes that are located within multiple cellular organelles. Examples of these biosynthetic pathways include the production of lipid membrane components and nucleotides. Biosynthesis is usually synonymous with anabolism.
Cyanophycin, also known as CGP or multi-L-arginyl-poly, is a non-protein, non-ribosomally produced amino acid polymer composed of an aspartic acid backbone and arginine side groups.
Amino acid synthesis is the set of biochemical processes by which the amino acids are produced. The substrates for these processes are various compounds in the organism's diet or growth media. Not all organisms are able to synthesize all amino acids. For example, humans can synthesize 11 of the 20 standard amino acids. These 11 are called the non-essential amino acids).
L-Arginine:glycine amidinotransferase is the enzyme that catalyses the transfer of an amidino group from L-arginine to glycine. The products are L-ornithine and glycocyamine, also known as guanidinoacetate, the immediate precursor of creatine. Creatine and its phosphorylated form play a central role in the energy metabolism of muscle and nerve tissues. Creatine is in highest concentrations in the skeletal muscle, heart, spermatozoa and photoreceptor cells. Creatine helps buffer the rapid changes in ADP/ATP ratio in muscle and nerve cells during active periods. Creatine is also synthesized in other tissues, such as pancreas, kidneys, and liver, where amidinotransferase is located in the cytoplasm, including the intermembrane space of the mitochondria, of the cells that make up those tissues.
Cerebral creatine deficiencies are a small group of inherited disorders that result from defects in creatine biosynthesis and utilization. Commonly affected tissues include the brain and muscles. There are three distinct CCDs. The most common is creatine transporter defect (CTD), an X-linked disorder caused by pathogenic variants in SLC6A8. The main symptoms of CTD are intellectual disability and developmental delay, and these are caused by a lack of creatine in the brain, due to the defective transporter. There are also two enzymatic defects of creatine biosynthesis, arginine:glycine amidinotransferase deficiency, caused by variants in GATM and guanidinoacetate methyltransferase deficiency, caused by variants in GAMT. The single enzyme defects are both inherited in an autosomal recessive manner.
Glycocyamine is a metabolite of glycine in which the amino group has been converted into a guanidine by guanylation. In vertebrate organism it is then transformed into creatine by methylation.
Nitroarginine, or Nω-nitro-l-arginine, also known as L-NOARG, is a nitro derivative of the amino acid arginine. It is an inhibitor of nitric oxide synthase and hence a vasoconstrictor. As such, it finds widespread use as a biochemical tool in the study of nitric oxide and its biological effects.
Protein detoxification is the process by which proteins containing methylated arginine are broken down and removed from the body.
L-Homocitrulline is an amino acid and a metabolite of ornithine in mammalian metabolism. The amino acid can be detected in larger amounts in the urine of individuals with urea cycle disorders. At present, it is thought that the depletion of the ornithine supply causes the accumulation of carbamyl-phosphate in the urea cycle which may be responsible for the enhanced synthesis of homocitrulline and homoarginine. Both amino acids can be detected in urine. Amino acid analysis allows for the quantitative analysis of these amino acid metabolites in biological fluids such as urine or blood.
Citrullinemia type I (CTLN1), also known as arginosuccinate synthetase deficiency, is a rare disease caused by a deficiency in argininosuccinate synthetase, an enzyme involved in excreting excess nitrogen from the body. There are mild and severe forms of the disease, which is one of the urea cycle disorders.